With capacity for 35 patients and healthy volunteers, the extension brings the total number of Phase I beds in London to 105 and globally to 385. This is expected to increase further in late 2010, with the opening of a Phase I unit in Hyderabad, India, initially with 50 beds, and with capacity for expansion to 100.
Quintiles said that the electronic data capture and automated workflow systems link Quintiles Phase I facilities around the world, to provide harmonised data and reporting across multiple sites.
The company is expecting to work closely with experts from the biomedical research centres (BRC) as appropriate, to drive forward the translation of science onto the wards -from ‘bench to bedside’.
Eddie Caffrey, senior vice president of global Phase I at Quintiles, said: “Declining productivity in research and development means that the biopharmaceutical industry is under intense pressure to increase efficiency and overcome complexity.
“Effective early-stage development can have significant impact on speed and cost of the overall development process. Our customers need a holistic solution that combines fast and cost-efficient regulatory studies with advanced scientific expertise and techniques such as modeling and simulation, biomarkers and microdosing for more complex studies.
“With our expanded facility in London and our planned facility in Hyderabad we will be better able to provide an integrated Phase I research solution that facilitates robust decision making early.”